SYRS News and Press, Syros Pharmaceuticals Inc. From 11/20/18

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare Conference. Details a...

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more ...

Syros Pharmaceuticals, Inc. (SYRS) Q3 2018 Results Earnings Conference Call November 01, 2018 07:30 AM ET Executives Naomi Aoki - VP, Corporate Communications and IR Dr. Nancy Simonian - CEO Dr. David Roth - Chief Medical Officer Dr. Eric Olson - Chief Scientific Officer Joe ...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present initial clinical data from both combination cohorts in its ongoing Phase 2 trial of SY-1425, its first-in-class selective retinoi...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q3 GAAP EPS of -$0.47 misses by $0.01 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...

Opened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies Dose Escalation Data from Phase 1 Trial of ...

First Clinical Data from Phase 1 Trial of SY-1365 in Advanced Solid Tumors to be Highlighted in Oral Plenary Session Preclinical Data on Oral CDK7 Inhibitor Program to be Unveiled in Poster Session Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines tha...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Morgan Stanley 16th Annual Global...

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cree, Inc. (NASDAQ:CREE), ArcBest Corporation (NASDAQ:ARCB), Syros Pharma...